The dawn of a revolution in personalized lung cancer prevention

Cancer Prevention Research

Volumn 4, Issue 7, 2011, Pages 949-953

  Khuri, Fadlo R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; BEXAROTENE; CELECOXIB; ERLOTINIB; EVEROLIMUS; ILOPROST; PLACEBO;

CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; CARCINOGENESIS; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; LUNG CANCER; MOLECULAR BIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMOKING; TOBACCO DEPENDENCE;

CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PYRAZOLES; SMOKING; SULFONAMIDES;

EID: 79960075595     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0278     Document Type: Review

References (40)

1. The alpha-tocopherol beta-carotene Cancer Prevention Study Group: The effect of Vitamin E and beta carotene on the incidence of lung cancers in male smokers. N Engl J Med 1994;330:1029-35
2. Omenn GS, Goodman GE, Thornquist M. Effects of combination of beta-carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150-5 (Pubitemid 26137973)
3. Hennekens CH, Buring JE, Manson JE. Lack of long term supplementation with beta-carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996;334:1145-9 (Pubitemid 26137972)
4. van Zandwijk N, Dalesio O, Pastorino U, de Vries N, van Tinteren H. EUROSCAN, a randomized trial of chemoprevention with vitamin A, and N-acetylcysteine in patients with head and neck cancer or lung cancer. J Natl Cancer Inst 2000;92:977-86. (Pubitemid 30469963)
5. Lippman SM, Lee JJ, Karp DD, Vokes EE, Benner SE, Goodman GE, et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage-I non-small cell lung cancer. J Natl Cancer Inst 200193:605-18.
6. Karp DD, Lee SJ, Shaw Wright GL, Johnson DH, Johnson MR, Goodman GE, et al. MDACC Thoracic Chemoprevention Research Group. A phase III, intergroup, randomized, double-blind, chemoprevention trial of selenium (Se) supplementation in resected stage I non-small cell lung cancer (NSCLC). Proceedings of ASCO 2010;28abs CRA7004.
7. Bach PB, Silvestri GA, Hanger M, Jett JR. American College of Chest Physicians. Screening for lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132(3 Suppl):69S-77S
8. Aberle DR, Adams AM, Berg CD, Clapp JD, Clingan KL, Gareen IF, et al. National Lung Screening Trial Research Team. Baseline characteristics of participants in the randomized national lung screening trial. J Natl Cancer Inst 102:1171-9, 2010.
9. Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, Miettinen OS. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006;355:1763-71. Erratum in: N Engl J Med 2008;359:877; N Engl J Med 2008;358:1862; N Engl J Med 2008;358:1875.
10. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011;377:31-41.
11. Kim ES, Hong WK, Lee JJ, Mao L, Rodolfo CM, Liu DD, et al. Biological activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prev Res 2010;3:148-59.
12. Mao JT, Roth MD, Fishbein MC, Aberle DR, Zhang Z-F, Rao JY, et al. Lung cancer chemoprevention with celecoxib in former-smokers. Cancer Prev Res 2011;4:984-93.
13. Keith RL, Blatchford PJ, Kittelson J, Minna JD, Kelly K, Massion PP, et al. Oral iloprost improves endobronchial dysplasia in former smokers. Cancer Prev Res 2011;4:793-802.
14. Park ER, Japuntich S, Temel J, Lanuti M, Pandiscio J, Hilgenberg J, et al. A smoking cessation intervention for thoracic surgery and oncology clinics: A pilot trial. J Thorac Oncol 2011;6:1059-65.
15. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global Cancer Statistics. CA Cancer J Clin 2011;61:69-90. Erratum in: CA Cancer J Clin. 612:134, 2011.
16. Ramalingam SS, Owonikoko TK, Khuri FR. Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin 2011;61:91-112.
17. Gold KA, Kim ES, Lee JJ, Wistuba II, Farhangfar CJ, Hong WK. The BATTLE to personalize lung cancer prevention through reverse migration. Cancer Prev Res 2011;4:962-72.
18. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011;1:44-53.
19. Lee JS, Lippman SM, Benner SE, Lee JJ, Ro JY, Lukeman JM, et al. Randomized placebo-controlled trial of isotetinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol 1994;12:937-45. (Pubitemid 24145320)
20. Kurie JM, Lotan R, Lee J, Lee JS, Morice RC, Liu D, et al. Treatment of former smokers with 9-cis retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium. Journal of the National Cancer Institute 2003;95:206-14. (Pubitemid 36240633)
21. Huang M, Stolina M, Sharma S, Mao J, Zhu L, Miller P, et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance of lymphocytes and macrophages: up-regulation of interleukin 12 production. Cancer Res 1998;58:1208-16. (Pubitemid 28183210)
22. Rioux N, Castonguay A. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicyclic acid and NS-398. Cancer Res 1998;58:5354-60. (Pubitemid 28551116)
23. Menter DG, Schilsky RL, Dubois RN. Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res 2010;5:1384-90.
24. Khuri FR, Wu H, Lee JJ, Kemp BL, Lotan R, Lippman SM, et al. Cyclooxygenase-2 over-expression correlates is a marker of poor prognosis in stage I non-small cell lung cancer. Clinical Cancer Research 2001;7:861-7. (Pubitemid 32708722)
25. Mao JT, Roth MD, Serio KJ, Baratelli F, Zhu L, Holmes EC, et al. Celecoxib modulates the capacity for prostaglandin E2 and interleukin-10 production in alveolar macrophases from active smokers. Clin Cancer Res 2003;9:5835-41. (Pubitemid 38018065)
26. Mao JT, Tsu IH, Dubinett SM, Adams B, Sarafian T, Baratelli F, et al. Modulation of pulmonary leukotriene B4 production by cyclooxygenase-2 inhibitors and lipopolysaccharide. Clin Cancer Res 2004;10:6872-8. (Pubitemid 39383036)
27. Mao JT, Fishbein MD, Adams B, Roth MD, Goodglick L, Hong L, et al. Celecoxib decreases Ki-67 proliferative index in active smokers. Clin Cancer Res 2006;12:314-20. (Pubitemid 43166209)
28. Szabo E. Assessing efficacy in early-phase cancer prevention clinical trials: the case of Ki-67 in the lung. Cancer Prev Res 2010;3:128-31.
29. Ochoa CE, Mirabolfathinejad SG, Ruiz VA, Evans SE, Gagea M, Evans CM, et al. Interleukin 6, but not T helper 2 cytokines, promotes lung carcinogenesis. Cancer Prev Res 2011;4:51-64.
30. Ivanov AI, Scheck AC, Romanovsky AA. Expression of genes controlling transport and catabolism of prostaglandin E2 in lipopolysaccharide fever. Am J Physiol Regul Integr Comp Physiol 2003;284:R698-706.
31. Edelman MJ, Watson D, Wang X, Morrison C, Kratzke RA, Jewell S, et al. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy-Cancer and Leukemia Group B Trial 30203. J Clin Oncol 2008;26:848-55 (Pubitemid 351398075)
32. Konstantin H, Dragnev KH, Tian Ma T, Cyrus J, Galimberti F, Memoli V, et al. Bexarotene plus erlotinib suppresses lung carcinogenesis independent ofKRASmutations in two clinical trials and transgenic models. Cancer Prev Res 2011;4:818-28.
33. Veronesi G, Szabo E, Decensi A, Guerrieri-Gonzaga A, Bellomi M, Radice D, et al. Randomized phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected lung nodules. Cancer Prev Res 2011;4:34-42.
34. Sharyl J. Nass, Harold L. Moses, John Mendelsohn, editors;Institute of Medicine of the National Academies. A national cancer clinical trials system for the 21st century. Reinvigorating the NCI cooperative group program. Washington DC: The National Academies Press, 2010.
35. Owonikoko TK, Force S, Sica G, Bechara R, Harvey RD, Sun S-Y, et al. A phase IB Window of Opportunity Clinical Study with Everolimus in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC). Abstract #564. Presented at ASCO Annual Meeting 2011.
36. West KA, Brognard J, Clark AS, Linnoila IR, Yang X, Swain SM, et al. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest 2003;111:81-90. (Pubitemid 36134851)
37. Gustafson AM, Soldi R, Anderlind C, Scholand MB, Qian J, Zhang X, et al. Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci Transl Med 2010;2:26ra25.
38. 123I]-celecoxib analogs as SPECT tracers of cyclooxygenase-2 in inflammation. ACS Med Chem Lett 2011;2:160-4.
39. Beane J, Vick J, Schembri F, Anderlind C, Gower A, Campbell J, et al. Characterizing the impact of smoking and lung cancer on the airway transcriptome using RNA-Seq. Cancer Prev Res 2011;4:803-17.
40. Blackburn EH. Cancer Interception. Cancer Prev Res 2011;4:787-92.